Aarey Drugs Peer Comparison

NSE: AAREYDRUGS | BSE: 524412

₹101.57

₹1.31 (1.31%)

As on 25-Sep-2026IST

Market cap

₹312 Cr

Revenue (TTM)

₹415 Cr

P/E Ratio

74.8

P/B Ratio

1.9

Div. Yield

0 %

Edit

	Aarey Drugs	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Market cap (₹ Cr)	312	36,827	27,985	27,762	26,788
Revenue (₹ Cr)	415	3,564	9,205	1,936	1,462
Net Profit (₹ Cr)	4.18	414.00	-371.81	288.22	387.35
Net Margin (%)	0.99	11.23	-3.93	14.79	26.01
RoE (%)	2.79	8.38	-3.85	29.77	25.18
Price to Earnings	74.79	90.04	--	96.32	69.36
Price-To-Book	1.91	7.32	3.50	20.68	15.53

Income Statement (₹ Cr)

	Aarey Drugs	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Operating Revenue	414.69	3,564.00	9,205.28	1,935.80	1,461.80
Total Income	420.95	3,686.00	9,449.59	1,948.58	1,489.25
Total Expenditure	407.89	2,792.00	8,195.15	1,485.56	919.25
EBITDA	6.80	772.00	1,010.13	450.24	542.56
Depreciation	3.22	226.00	857.51	50.83	37.68
EBIT	3.58	546.00	152.62	399.41	504.88
Interest	5.64	217.00	342.73	40.84	3.77
Other Income	6.26	122.00	244.31	12.78	27.45
Exceptional Items	0.00	12.00	-216.88	0.00	0.00
Profit before Tax	4.20	463.00	-162.68	371.35	528.56
Provision for Tax	0.03	49.00	209.13	83.14	141.21
Profit after Tax	4.18	414.00	-371.81	288.22	387.35

	Aarey Drugs	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Shareholder's Funds	150.42	4,940.00	8,162.62	1,288.82	1,653.56
Minority Interest	0.00	-5.00	0.00	0.00	-1.13
Non-Current Liabilities	1.75	1,712.00	5,044.14	202.03	42.40
Current Liabilities	145.08	1,622.00	4,758.28	835.87	230.82
Total Liabilities	290.59	8,100.00	15,513.53	1,451.43	1,549.26

	Aarey Drugs	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Non-Current Assets	27.89	5,343.00	10,211.52	519.60	1,026.85
Current Assets	262.94	2,606.00	7,191.66	1,681.81	881.27
Total Assets	290.59	8,100.00	15,513.53	1,451.43	1,549.26
Total Debt*	34.86	1,859.00	4,720.27	393.17	8.18
Net Current Assets	117.87	984.00	2,433.38	845.94	650.46
Contingent Liabilities	--	770.26	99.76	12.25	15.38

	Aarey Drugs	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Cash From Operating Activities	10.30	-22.00	892.30	159.18	118.34
Cash Flow from Investing Activities	-5.94	-783.00	-477.46	-64.81	-223.94
Cash from Financing Activities	-4.48	409.00	-440.83	-39.81	261.12
Net Cash Inflow / Outflow	-0.12	-396.00	-25.99	54.56	155.52

	Aarey Drugs	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
ROCE (%)	6.38	4.07	6.61	26.97	20.14
ROE (%)	2.79	8.38	-3.85	29.77	25.18
ROA (%)	1.42	4.94	-2.21	24.77	21.93
EBIT Margin (%)	0.86	15.32	1.66	20.63	34.54
Net Margin (%)	0.99	11.23	-3.93	14.79	26.01
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Aarey Drugs	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Revenue Growth (%)	-7.69	18.37	0.78	46.65	40.90
EBIT Growth (%)	146.05	252.26	-70.53	62.13	124.50
Net Profit Growth (%)	0.51	377.85	-1,383.43	89.49	104.15
EPS Growth (%)	-0.04	1,001.33	-484.84	78.60	42.32
Book Value Growth (%)	4.34	29.77	2.28	42.49	94.96

	Aarey Drugs	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Price / Earnings	68.69	92.42	-89.43	94.85	69.36
Price / Book Value	1.91	7.32	3.50	20.68	15.53
Dividend Yield (%)	0.00	0.00	0.00	0.09	0.08
EV/EBITDA	50.88	49.60	31.80	61.47	49.01
Market Cap (₹ Cr)	95.93	23,064.69	29,731.27	0.00	19,988.69

	Aarey Drugs	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Debt to Equity	0.01	0.31	0.53	0.11	0.01
Short term debt to equity ratio	0.24	0.11	0.12	0.54	0.02
Current Ratio	1.81	1.61	1.51	2.01	3.82
Quick Ratio	1.53	1.06	0.87	1.14	2.82
Interest Coverage	1.75	3.13	0.53	10.09	141.16

	Aarey Drugs	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Debtors to sales (%)	31.27	16.50	23.44	26.28	24.80
Asset Turnover	1.41	0.43	0.55	1.66	0.83
Receivable days	122.43	60.36	77.05	47.59	90.06
Inventory Days	30.87	64.42	77.13	62.58	61.02
Payable days	93.08	218.94	173.49	228.78	96.06
Cash Conversion Cycle	60.21	-94.15	-19.30	-118.62	55.02

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.